×
About 360 results

ALLMedicine™ Protoporphyria Center

Research & Reviews  121 results

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoetic Protoporphyria or X-Linked Protoporphyria
https://clinicaltrials.gov/ct2/show/NCT04402489

Dec 23rd, 2021 - The primary objective of this study is to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, or stinging) associated with sunlight exposure in subjects with EPP or XLP aged 12-75.

Liver involvement in patients with erythropoietic protoporphyria: retrospective analysi...
https://doi.org/10.1016/j.anndiagpath.2021.151859
Annals of Diagnostic Pathology; Zhao C, Guan JX et. al.

Nov 30th, 2021 - Erythropoietic protoporphyria (EPP) is a rare inherited disease whose morbidity is about 1:75,000 to 1:200,000. It is caused by the deficiency of porphyrin ferrochelatase (FECH). Liver involvement in EPP is even rarer. The diagnosis of EPP with li...

The effect of vitamin D recommendations on serum 25-hydroxyvitamin D level in patients ...
https://doi.org/10.1016/j.nut.2021.111477
Nutrition (Burbank, Los Angeles County, Calif.); Heerfordt IM, Lerche CM et. al.

Nov 12th, 2021 - Patients with erythropoietic protoporphyria (EPP) avoid sun exposure owing to photosensitivity. For decades, sun-avoiding Danes have been recommended daily vitamin D supplements all year. We offered our EPP patients serum 25-hydroxyvitamin D (25(O...

Hematopoietic stem cell transplant for erythropoietic porphyrias in pediatric patients.
https://doi.org/10.1002/pbc.29231
Pediatric Blood & Cancer; Wang YM, Gloude NJ et. al.

Jul 11th, 2021 - Cutaneous, hematopoietic, and hepatic manifestations of congenital erythropoietic porphyria (CEP) and erythropoietic protoporphyria (EPP) can be debilitating. We present our institution's experience with five patients with porphyria who underwent ...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  5 results

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoetic Protoporphyria or X-Linked Protoporphyria
https://clinicaltrials.gov/ct2/show/NCT04402489

Dec 23rd, 2021 - The primary objective of this study is to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, or stinging) associated with sunlight exposure in subjects with EPP or XLP aged 12-75.

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
https://clinicaltrials.gov/ct2/show/NCT03520036

Sep 30th, 2020 - This is a Phase 2, randomized, double-blind, placebo controlled study to assess the efficacy, tolerability, and safety of MT-7117 in subjects with EPP. The study consists of a 2 week screening period, a 16 week double-blind treatment period, and a...

Multicentre Phase III Erythropoietic Protoporphyria Study
https://clinicaltrials.gov/ct2/show/NCT04053270

Oct 10th, 2019 - Afamelanotide is a man-made drug being studied for use as a preventative medication for Erythropoietic Protoporphyria (EPP) sufferers. It is a synthetically produced analogue of human alpha melanocyte stimulating hormone (alpha-MSH). The study wil...

Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria
https://clinicaltrials.gov/ct2/show/NCT01550705

Jan 16th, 2017 - Clinically, both erythropoietic protoporphyria (EPP) and X-linked EPP (XLEPP) are characterized by painful, non-blistering cutaneous photosensitivity with onset in early childhood. EPP is the most common porphyria in children and the third most co...

see more →

News  16 results

Photoprotection Recommended for People of Color
https://www.medscape.com/viewarticle/951252

May 17th, 2021 - Dermatologists and other clinicians should advise their patients with skin of color to practice sensible sun protection, including wearing protective clothing, staying in the shade when outdoors, and applying a tinted sunscreen with an SPF of 30 o...

Novel Oral Drug Improves Sunlight Tolerance in Patients With Erythropoietic Protoporphyria
https://www.medscape.com/viewarticle/936274

Aug 25th, 2020 - Dersimelagon, a novel once-daily oral selective melanocortin-1 receptor agonist, significantly boosted sunlight tolerance in patients with erythropoietic protoporphyria in a multicenter, phase 2, randomized trial, Kirstine Belongie, PhD, reported ...

Novel oral drug improves sunlight tolerance in patients with erythropoietic protoporphyria
https://www.mdedge.com/dermatology/article/227395/rare-diseases/novel-oral-drug-improves-sunlight-tolerance-patients
Bruce Jancin

Aug 24th, 2020 - Dersimelagon, a novel once-daily oral selective melanocortin-1 receptor agonist, significantly boosted sunlight tolerance in patients with erythropoietic protoporphyria in a multicenter, phase 2, randomized trial, Kirstine Belongie, PhD, reported.

FDA OKs New Treatment Afamelanotide for Phototoxic Reactions
https://www.medscape.com/viewarticle/919622

Oct 8th, 2019 - The US Food and Drug Administration (FDA) has approved afamelanotide (Scenesse, Clinuvel), the first treatment to ease phototoxic reactions in patients with erythropoietic protoporphyria, according to an agency news release. Erythropoietic protopo...

Team identifies mutation that causes EPP
https://www.mdedge.com/hematology-oncology/article/185441/anemia/team-identifies-mutation-causes-epp
HT Staff

Sep 10th, 2017 - Red blood cells Researchers say they have discovered a genetic mutation that triggers erythropoietic protoporphyria (EPP). The team performed genetic sequencing on members of a family from Northern France who had EPP of a previously unknown geneti.

see more →